文献速递肝病消化内镜

胆汁酸盐分流、口服胆汁酸盐激发试验与门静脉高压的内镜下病变:SHUNT-V研究

Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study.
PubMed 文献 · Aliment Pharmacol Ther · 2024-11-10

SHUNT-V多中心研究纳入306例代偿期肝硬化患者,评估基于胆汁酸盐清除率的疾病严重度指数(DSI)对食管静脉曲张及其他门静脉高压内镜病变的检出能力。DSI≤18.3作为排除大食管静脉曲张的界值,灵敏度达96.3%–100%,若单独用于推迟内镜,可避免27%–35%的内镜检查。

要点

  • DSI对LEV的AUROC为0.81–0.82,对所有显著PH病变为0.79–0.80。
  • DSI≤18.3排除LEV的灵敏度为96.3%–100%,排除所有显著PH病变为97.3%–100%。
  • 以DSI≤18.3推迟内镜可避免27%–35%的EGD,漏诊LEV 0%–3.7%。

核心结论

  • HepQuant DSI可预测不同患者特征和病因谱下LEV及显著PH病变的可能性。
  • 基于肝功能和门体分流的DSI可辅助Child-Pugh A肝硬化患者推迟静脉曲张内镜检查的决策。

研究设计与样本

  • 美国多中心SHUNT-V研究,纳入计划接受内镜筛查静脉曲张的成年代偿期肝硬化受试者。
  • SHUNT-V入组306例受试者,275例同时具有DSI和内镜检查结果,238例为Child-Pugh A肝硬化。

主要发现

  • 238例Child-Pugh A肝硬化中,52.1%为MASLD/MASH,25.2%为慢性丙型肝炎,15.6%为酒精性肝病;87%超重,64%肥胖,54%患糖尿病。
  • DSI对LEV的AUROC为0.81–0.82,对所有显著PH病变的AUROC为0.79–0.80。
  • DSI 18.3对LEV的灵敏度为96.3%–100%,对所有显著PH病变的灵敏度为97.3%–100%。
  • 若以DSI≤18.3作为推迟EGD的唯一决定因素,可避免27%–35%的EGD,漏诊LEV 0%–3.7%,漏诊所有显著PH病变0%–2.7%。

关键数值与推荐

  • DSI由口服和静脉给予标记胆汁酸盐后的清除率计算。
  • DSI≤18.3作为排除LEV的界值,可接受标准为阴性似然比<0.52且灵敏度>85%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The accuracy of current criteria for ruling out large oesophageal varices (LEV) and other endoscopic lesions of portal hypertension (PH) may be compromised by obesity and MASLD/MASH. AIMS: In the US multicentre SHUNT-V study, we evaluated the disease severity index (DSI) for detecting LEV and other lesions of PH at endoscopy. METHODS: Subjects were adults with compensated cirrhosis scheduled for endoscopy to screen for varices. DSI was calculated from clearances of labelled cholates after oral and intravenous administration. DSI ≤ 18.3 was evaluated as a cut-off for ruling out LEV with acceptance criteria of negative likelihood ratio < 0.52 and sensitivity > 85%. RESULTS: SHUNT-V enrolled 306 subjects; 275 had both DSI and endoscopy, and 238 had Child-Pugh A cirrhosis (52.1% MASLD/MASH, 25.2% chronic hepatitis C and 15.6% alcoholic liver disease; 87% were overweight, 64% were obese and 54% had diabetes). AUROCs for DSI ranged from 0.81 to 0.82 for LEV and 0.79 to 0.80 for all significant PH lesions. DSI 18.3 had sensitivity 96.3%-100% for LEV and 97.3%-100% for all significant PH lesions. If DSI ≤ 18.3 were used as the sole determinant to defer EGD, 27%-35% of EGDs could have been avoided with 0%-3.7% of LEV and 0%-2.7% of all significant PH lesions missed. CONCLUSIONS: HepQuant DSI predicts the likelihood of LEV and significant PH lesions across a spectrum of patient characteristics and disease aetiologies. DSI, based on liver function and portal-systemic shunting, can aid in the decision to defer endoscopy for varices in patients with Child-Pugh A cirrhosis. TRIAL REGISTRATION: The SHUNT-V study was registered at ClinicalTrials.gov (NCT03583996).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Shiffman M, Reddy KR, Leise MD, et al. Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study. Aliment Pharmacol Ther. 2024. PMID: 39523681. doi:10.1111/apt.18386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。